Is azilsartan superior to other angiotension receptor blockers in regard to cardiorenal outcome data?

In short, there are no data. There are very few head-to-head comparisons of ARBs on hard outcomes. Azilsartan was used in SPRINT (alongside losartan and valsartan), though the secondary analyses focused on class effect as opposed to specific med-to-med comparisons within a class (DeCarolis et al., PMID 35259925). Azilsartan has been associated with reduced LV mass and reduced albuminuria, though these effects were likely due to improved BP lowering.